看看这个分析,我又56.10买了DNDN# Stock
O*L
1 楼
Dendreon Pricing Comes in Higher-than-Expected
Dendreon Corporation (DNDN, Free Analysis), a biotechnology company focused
on cancer treatments, saw its shares jump sharply higher in early trading
after confirming approval of Provenge by the FDA and saying that its pricing
point would be around $93,000 annually, which is much higher than many
analysts were expecting.
As a result, some analysts are projecting hefty profits for the biotech firm
, ranging from $1.1 billion in 2014 to $4.3 billion b
Dendreon Corporation (DNDN, Free Analysis), a biotechnology company focused
on cancer treatments, saw its shares jump sharply higher in early trading
after confirming approval of Provenge by the FDA and saying that its pricing
point would be around $93,000 annually, which is much higher than many
analysts were expecting.
As a result, some analysts are projecting hefty profits for the biotech firm
, ranging from $1.1 billion in 2014 to $4.3 billion b